ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SANG vs HCAT // OPERATING MARGIN

Sangoma Technologies Corporation (NASDAQ) VS. Health Catalyst Inc (NASDAQ) • 15-METRIC TALLY: SANG 2 — HCAT 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SANG VS. HCAT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SANG HCAT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) — -35.00% — TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -0.18% — TIE /fcf-yield <GO>
Operating Margin ACTIVE — -51.70% — TIE /operating-margins <GO>
Net Profit Margin — -57.20% — TIE /net-margins <GO>
Revenue Growth (YoY) — 1.50% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality — 4/9 — TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 56.4 46.8 +9.64 SANG /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $157.9M $134.7M $23.1M SANG /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SANG REV HCAT REV SANG GROSS % HCAT GROSS % SANG FCF HCAT FCF
FY 2025 — $311.1M — — — -$237.0K
FY 2024 — $306.6M — — — $12.9M
FY 2023 — $295.9M — — — -$33.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SANG // BETA —
HCAT // BETA —